Provided by Tiger Fintech (Singapore) Pte. Ltd.

Denali Therapeutics Inc.

15.34
-1.3500-8.09%
Volume:405.55K
Turnover:6.43M
Market Cap:2.23B
PE:-5.97
High:16.53
Open:16.36
Low:15.16
Close:16.69
Loading ...

Denali Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Feb

Denali Therapeutics Inc Files for Mixed Shelf; Size Not Disclosed - SEC Filing

THOMSON REUTERS
·
28 Feb

BRIEF-Denali Therapeutics Q4 Operating Income USD -129.846 Million

Reuters
·
28 Feb

Denali Therapeutics Inc - Expects 10%-15% Increase in Cash Operating Expenses for 2025

THOMSON REUTERS
·
28 Feb

Denali Therapeutics (DNLI) Gets a Buy from Stifel Nicolaus

TIPRANKS
·
10 Feb

DNLI Reports Upbeat Longer-Term Data From Hunter Syndrome Study

Zacks
·
07 Feb

Denali Therapeutics announces primary analysis of Phase 1/2 study in MPS II

TIPRANKS
·
07 Feb

BRIEF-Denali Therapeutics Announces Primary Analysis & Long-Term Follow-Up Of Phase 1/2 Study In Hunter Syndrome With Tividenofusp Alfa

Reuters
·
07 Feb

Denali Therapeutics Inc: Long-Term Safety Data Demonstrate That Tividenofusp Alfa Was Generally Well Tolerated

THOMSON REUTERS
·
07 Feb

Denali Therapeutics: Tividenofusp Alfa U.S. Launch Preparation Ongoing to Deliver Tividenofusp Alfa to Families With Mps Ii in Late 2025 or Early 2026

THOMSON REUTERS
·
07 Feb

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-up of Phase 1/2 Study in Hunter Syndrome (Mps Ii) With Tividenofusp Alfa

THOMSON REUTERS
·
07 Feb

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

GlobeNewswire
·
07 Feb

Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (Mps Ii) and Transportvehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 Worldsymposium™

THOMSON REUTERS
·
30 Jan

Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™

GlobeNewswire
·
30 Jan

Denali Gains 26.6% in a Year: How Should You Play the Stock?

Zacks
·
21 Jan

Why Denali Therapeutics (DNLI) Is the Biotech Stock with Biggest Upside Potential

Insider Monkey
·
18 Jan